,i #aadth ,,congress #ast ,session ,h4 ,r4 #ajff ,,in ,,the ,,house ,,of ,,representatives ,february #be1 #bjae ,mr4 ,collins of ,new ,york 7for himself and ,mr4 ,pompeo7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to promote the use of adaptive trial designs1 ,bayesian methods1 and other innovative statistical methods in clinical protocols for drugs1 biological products1 and devices1 and with respect to the requirement to conduct postapproval studies and clinical trials1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,clinical ,trials ,modernization ,act of #bjae4 #b4 ,clinical trial modernization 7a7 ,proposals for use of innovative statistical methods in clinical protocols for drugs1 biological products1 and devices ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #ejf;,f 7#ba ,u4,s4,c4 #cef;f7 the following new section3 #ejg4 ,clinical trial modernization 7a7 ,in general ,to promote the efficiency of the development and regulatory review and approval1 licensure1 or clearance of drugs1 biological products1 and devices and the timely availability of innovative treatments1 the ,secretary shall1 after providing notice and an opportunity for public comment1 establish and implement a framework through which-- 7#a7 sponsors of drugs1 biological products1 or devices may submit to the ,secretary a proposal for the incorporation of adaptive trial designs1 ,bayesian methods1 or other alternative statistical methods into proposed clinical protocols and marketing applications for drugs1 biological products1 or devices2 and 7#b7 the ,secretary will commit to timelines for reviewing and providing feedback on proposals so submitted4 4 7b7 ,guidance addressing use of adaptive trial designs and ,bayesian methods 7#a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs 7in this subsection referred to as the ,secretary71 shall-- 7,a7 update and finalize the draft guidance addressing the use of adaptive trial design for drugs and biological products2 and 7,b7 issue draft guidance on the use of ,bayesian methods in the development and regulatory review and approval1 licensure1 or clearance of drugs1 biological products1 and devices4 7#b7 ,contents ,the guidances under paragraph 7#a7 shall-- 7,a7 establish or clarify standards for using adaptive trial designs and ,bayesian methods in clinical trials1 including clinical trials that form the primary basis for approval1 clearance1 or licensure of the products involved 7such as trials that provide substantial evidence for the approval of drugs72 7,b7 establish a mechanism for sponsors to obtain feedback from the ,secretary under section #ejg1 as added by subsection 7a71 on technical issues related to modeling and simulations prior to-- 7i7 completion of such modeling or simulations2 or 7ii7 the submission of resulting information to the ,secretary2 7,c7 specify the types of quantitative and qualitative information required for review2 and 7,d7 specify the recommended analysis methodology4 7#c7 ,public meeting ,prior to updating or developing the guidances required by paragraph 7#a71 the ,secretary shall consult1 through a public meeting to be held no later than #a year after the date of enactment of this ,act1 with stakeholders including representatives of regulated industry1 academia1 patient advocacy organizations1 and disease research foundations4 7#d7 ,schedule ,the ,secretary shall1 after providing notice and opportunity for public comment1 publish-- 7,a7 the final guidance required by paragraph 7#a77;,a7 not later than #f months after the date of the public meeting required by paragraph 7#c72 and 7,b7 the guidance required by paragraph 7#a77;,b7 not later than #ab months after the date of the public meeting required by paragraph 7#c74 7#e7 ,review and revision of guidance documents ,not later than #dh months after the date of enactment of this ,act1 the ,secretary shall review and1 as appropriate1 revise the guidance documents required by subparagraphs 7,a7 and 7,b7 of paragraph 7#a7 to reflect developments in statistical methods that could be appropriate for use in clinical trials1 including clinical trials that-- 7,a7 form the primary basis for approval1 clearance1 or licensure of drugs1 biological products or devices2 or 7,b7 provide substantial evidence for the approval of drugs4 #c4 ,evaluations of required postapproval studies and clinical trials 7a7 ,in general ,section #eje7o77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7o77#c77 is amended by adding at the end the following new subparagraph3 7,g7 ,evaluations of required postapproval studies and clinical trials 7i7 ,in general ,the ,secretary shall establish a process under which the ,secretary1 on the initiative of the ,secretary or at the request of a responsible person1 shall periodically evaluate a postapproval study or clinical trial required to be conducted under this paragraph to determine whether-- 7,i7 the trial or study is no longer scientifically warranted2 or 7,,ii7 the design1 or the timelines applicable to the completion of1 the study or trial should be renegotiated because of changes in medical practice or the standard of care4 7ii7 ,not scientifically warranted ,in the case of a determination under clause 7i77,i7 that a postapproval study or clinical trial required to be conducted under this paragraph is no longer scientifically warranted1 the ,secretary shall no longer require the responsible person to conduct the study or trial4 7iii7 ,renegotiation ,in the case of a determination under clause 7i77,,ii7 that the design1 or the timelines applicable to the completion of1 a postapproval study or clinical trial required to be conducted under this paragraph should be renegotiated1 the ,secretary shall enter into negotiations with the responsible person to make such changes as may be necessary to such design or timelines as the ,secretary determines are necessary4 4 7b7 ,guidance ,not later than one year after the date of the enactment of this ,act1 the ,secretary shall issue draft guidance on the implementation of subparagraph 7,g7 of section #eje7o77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7o77#c771 as added by subsection 7a74 ,not later than two years after such date of enactment1 the ,secretary shall issue final guidance on such implementation4